Michael E. Allison
Impact in
- Hepatology top 0.2%
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Hepatocellular Carcinoma Treatment and Prognosis
- Epidemiology top 0.2%
- Liver Disease Diagnosis and Treatment
Papers in
- Hepatology 35
- Liver Disease and Transplantation 26
- Epidemiology 60
- Liver Disease Diagnosis and Treatment 57
- Co-authors
- Douglas T. Fearon (3 shared papers)Christopher Carl Goodnow (1 shared paper)Paul W. Dempsey (1 shared paper)Quentin Mark Anstee (8 shared papers)Chris Palmer (1 shared paper)Graeme J M Alexander (1 shared paper)Tim G. Wreghitt (1 shared paper)Antonio Vidal‐Puig (9 shared papers)
- Journals
- Journal of Hepatology (16 papers)Latin American Politics and Society (6 papers)Liver Transplantation (5 papers)The Lancet (4 papers)Transplantation (4 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Michael E. Allison
132 papers receiving 11.8k citations
Michael E. Allison's Hit Papers
Peers
Comparison fields: 5 of 171
- Hepatology 3.1k
- Epidemiology 6.2k
- Endocrinology, Diabetes and Metabolism 1.6k
- Transplantation 190
- Immunology 1.3k
Countries citing papers authored by Michael E. Allison
This map shows the geographic impact of Michael E. Allison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Allison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Allison more than expected).
Fields of papers citing papers by Michael E. Allison
This network shows the impact of papers produced by Michael E. Allison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Allison. The network helps show where Michael E. Allison may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael E. Allison, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 137 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Hit paper breakdown → | 2019 | 1091 |
| 2 | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Hit paper breakdown → | 2019 | 1063 |
| 3 | C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity Hit paper breakdown → | 1996 | 1022 |
| 4 | NASH limits anti-tumour surveillance in immunotherapy-treated HCC Hit paper breakdown → | 2021 | 1006 |
| 5 | FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study Hit paper breakdown → | 2020 | 640 |
| 6 | TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease Hit paper breakdown → | 2014 | 519 |
| 7 | Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Hit paper breakdown → | 2020 | 404 |
| 8 | 1994 | 402 | |
| 9 | Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆ Hit paper breakdown → | 2020 | 384 |
| 10 | Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis Hit paper breakdown → | 2020 | 341 |
| 11 | Observations on the ex situ perfusion of livers for transplantation Hit paper breakdown → | 2018 | 283 |
| 12 | Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease Hit paper breakdown → | 2020 | 278 |
| 13 | 2012 | 266 | |
| 14 | 2007 | 222 | |
| 15 | Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis Hit paper breakdown → | 2021 | 218 |
| 16 | 2016 | 170 | |
| 17 | 2016 | 163 | |
| 18 | An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD) Hit paper breakdown → | 2024 | 138 |
| 19 | 2015 | 136 | |
| 20 | 2009 | 134 |
About Michael E. Allison
Michael E. Allison is a scholar working on Hepatology, Epidemiology, Pathology and Forensic Medicine, Surgery and Transplantation, having authored 137 papers that have together received 12.1k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (57 papers), Liver Disease and Transplantation (26 papers), Organ Transplantation Techniques and Outcomes (18 papers), Alcohol Consumption and Health Effects (15 papers), Politics and Society in Latin America (7 papers), Diet, Metabolism, and Disease (7 papers), Renal Transplantation Outcomes and Treatments (6 papers) and Endoplasmic Reticulum Stress and Disease (6 papers). The work is most often cited by research in Hepatology (3.1k citations), Epidemiology (6.2k citations), Endocrinology, Diabetes and Metabolism (1.6k citations), Transplantation (190 citations) and Immunology (1.3k citations). Michael E. Allison has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Douglas T. Fearon, Christopher Carl Goodnow, Paul W. Dempsey, Quentin Mark Anstee, Chris Palmer, Graeme J M Alexander, Tim G. Wreghitt, Antonio Vidal‐Puig, Michèle Vacca and Philip Noel Newsome. Their work appears in journals such as Journal of Hepatology, Latin American Politics and Society, Liver Transplantation, The Lancet and Transplantation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.